The Latest Regenerative Medicine Articles from Streetwise Reports

Cellular Therapy Co. Earns Rare Pediatric Disease Designation for Infant Congenital Heart Treatment

Shares of Longeveron Inc. traded 50% higher after the company reported that the U.S. FDA approved its Lomecel-B for Rare Pediatric Disease Designation to treat a rare and life-threatening defect in infants called Hypoplastic Left Heart Syndrome. read more >

Alector Partners with GSK to Develop Monoclonal Antibodies for Neurodegenerative Diseases

Alector Inc. shares traded 59% higher after the company announced it entered into a global collaboration agreement with GlaxoSmithKline to develop and advance two first-in-class, clinical stage monoclonal antibodies for treating neurodegenerative diseases including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's and Alzheimer's. read more >

Intellia Shares Rise 49% on 'Landmark' Interim Results in Phase 1 ATTR Amyloidosis Trial

Intellia Therapeutics soared to a new 52-week high after the firm reported that in a Phase 1 clinical study with partner Regeneron, it had achieved "landmark clinical data" that demonstrated deep reduction in disease-causing protein after a single infusion of NTLA-2001, an investigational CRISPR therapy for transthyretin (ATTR) amyloidosis. read more >
Showing Results: 1 to 3 of 3

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"The market is discounting a near 100% chance EMO wins Aznalcóllar."
– Adam Schatzker, Research Capital Corporation
"MAG won't need any more money until free cash flow."
– Chen Lin, What Is Chen Buying? What Is Chen Selling?
"Buying LIO is like stealing."
– Bob Moriarty, 321 Gold